Results 271 to 280 of about 134,666 (283)

Current trends in development of HDAC-based chemotherapeutics.

Life Science, 2022
BACKGROUND Histone deacetylases (HDACs) are one of the essential epigenetic targets in cancer treatment. These enzymes play key roles in post-translation modification (PTM) and gene expression, and consequently, their inhibitors are about to find their ...
Narges Cheshmazar, Maryam Hamzeh-Mivehroud, H. N. Charoudeh, Salar Hemmati, Jelena Melesina, S. Dastmalchi   +5 more
semanticscholar   +1 more source

Chemo-proteomics exploration of HDAC degradability by small molecule degraders.

Cell Chemical Biology, 2021
Targeted protein degradation refers to the use of small molecules that recruit a ubiquitin ligase to a target protein for ubiquitination and subsequent proteasome-dependent degradation.
Yuan Xiong, K. Donovan, N. Eleuteri, Nadia Kirmani, Hong Yue, A. Razov, Noah M. Krupnick, R. Nowak, E. Fischer   +8 more
semanticscholar   +1 more source

Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)

Expert Opinion on Therapeutic Patents, 2020
Introduction: Histone deacetylase (HDAC) inhibitors play a crucial role in restoring the balance of acetylation and deacetylation of lysine residues of histones and non-histone proteins, which are applied to treat several diseases including cancer.
Chunlong Zhao, Hang Dong, Qifu Xu, Yingjie Zhang   +3 more
semanticscholar   +1 more source

Highly Potent Dual BET/HDAC Inhibitors for the Efficient Treatment of Pancreatic Cancer.

Angewandte Chemie, 2020
As one of the most aggressive and lethal human malignancies with extremely poor prognosis, there is an urgent demand of more effective therapy for the treatment of pancreatic cancer.
Shipeng He, Guoqiang Dong, Yu Li, Shanchao Wu, Wei Wang, C. Sheng   +5 more
semanticscholar   +1 more source

HDAC-targeting epigenetic modulators for cancer immunotherapy.

European journal of medicinal chemistry
HDAC inhibitors, which can inhibit the activity of HDAC enzymes, have been extensively studied in tumor immunotherapy and have shown potential therapeutic effects in cancer immunotherapy.
Binbin Cheng, Wei Pan, Yao Xiao, Zongbao Ding, Yingxing Zhou, Xiaoting Fei, Jin Liu, Zhenhong Su, Xiaopeng Peng, Jianjun Chen   +9 more
semanticscholar   +1 more source

Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.

European journal of medicinal chemistry, 2020
Despite the encouraging clinical progress of chemotherapeutic agents in cancer treatment, innovation and development of new effective anticancer candidates still represents a challenging endeavor. With 15 million death every year in 2030 according to the
Amr K. A. Bass, M. El-Zoghbi, El-Shimaa M. Nageeb, M. Mohamed, M. Badr, G. Abuo‐Rahma   +5 more
semanticscholar   +1 more source

Anticancer properties of chimeric HDAC and kinase inhibitors.

Seminars in Cancer Biology, 2020
Histone deacetylases (HDACs) are epigenetic regulators of chromatin condensation and decondensation and exert effects on the proliferation and spread of cancer. Thus, HDAC enzymes are promising drug targets for the treatment of cancer.
B. Biersack, Sibel Polat, M. Höpfner
semanticscholar   +1 more source

Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups.

Current Topics in Medicinal Chemistry, 2019
The state of histone acetylation plays a very crucial role in carcinogenesis and its development by chromatin remodeling and thus altering transcription of oncogenes and tumor suppressor genes.
Yan Li, F. Wang, Xiaoxue Chen, Jie Wang, Yonglong Zhao, Yongjun Li, Bin He   +6 more
semanticscholar   +1 more source

Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology

Drug Safety, 2019
R. Shah
semanticscholar   +1 more source

Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics

Advances in Cancer Research, 2018
Jesse J McClure, Xiaoyang Li, James C. Chou   +2 more
semanticscholar   +1 more source